Endpoint Selection in Randomized Clinical Trials for Hypertrophic Cardiomyopathy

Area of Science:

• Cardiology
• Genetics
• Clinical Trial Design

Background:

• Hypertrophic cardiomyopathy (HCM) research faces challenges due to rarity, low event rates, and diverse presentations.
• Genetic variations in sarcomeric protein genes (e.g., MYH7, MYBPC3) contribute to HCM's varied phenotypes and treatment responses.

Purpose of the Study:

• To explore the complexities and advancements in designing randomized clinical trials (RCTs) for hypertrophic cardiomyopathy.
• To identify clinically meaningful endpoints and discuss the integration of genetic insights and new technologies in HCM research.

Main Methods:

• Review of challenges in HCM clinical trial design, including endpoint selection and statistical considerations.
• Discussion of emerging therapies (e.g., gene therapy) and their impact on trial design.
• Analysis of current and future endpoint strategies, including patient-reported outcomes and hard clinical endpoints.

Main Results:

• RCTs for HCM are complicated by rarity, low event rates, and phenotypic diversity.
• Clinically meaningful endpoints are crucial but challenging to establish due to factors like test-retest variability.
• Genetic variability necessitates personalized trial approaches, with gene therapies showing promise.

Conclusions:

• Future HCM RCTs require integration of genetic insights and advanced technologies for improved design.
• A broader range of endpoints, including patient-reported outcomes and hard clinical events, is being considered.
• Personalized approaches and robust endpoint selection are key to enhancing patient outcomes in HCM trials.